Agreement | Jotup

dsm-firmenich announces repurchase of 1.5m shares to cover share plans

Retrieved on:

Monday, April 8, 2024

Agreement, Annual, Euronext Amsterdam, Share repurchase

KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, April 8, 2024 /PRNewswire/ -- dsm-firmenich today announces that, starting April 8, 2024, it intends to repurchase 1,500,000 ordinary shares to cover commitments under the Group's share-based compensation plans.

Key Points:

KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, April 8, 2024 /PRNewswire/ -- dsm-firmenich today announces that, starting April 8, 2024, it intends to repurchase 1,500,000 ordinary shares to cover commitments under the Group's share-based compensation plans.
The share repurchase is equivalent to approximately €156 million based on the closing price of the dsm-firmenich ordinary share on Euronext Amsterdam on April 4, 2024.
The program consists of an on-market share repurchase of 500,000 shares, followed by a repurchase of 1,000,000 shares by means of an equity forward transaction.
Other than the delivery of the shares under the equity forward transaction, the share repurchase program is anticipated to be completed in Q2 2024.

KARORA RESOURCES ANNOUNCES MERGER TRANSACTION WITH WESTGOLD RESOURCES

Retrieved on:

Monday, April 8, 2024

TORONTO, April 7, 2024 /CNW/ - Karora Resources Inc. (TSX: KRR) (OTCQX: KRRGF) ("Karora") and Westgold Resources Limited (ASX: WGX) (OTCQX: WGXRF) ("Westgold") have agreed to combine in a merger pursuant to which Westgold will acquire 100% of the issued and outstanding common shares of Karora ("Karora Shares") by way of a statutory plan of arrangement under the Canada Business Corporations Act ("CBCA") ("Transaction").

Key Points:

TORONTO, April 7, 2024 /CNW/ - Karora Resources Inc. (TSX: KRR) (OTCQX: KRRGF) ("Karora") and Westgold Resources Limited (ASX: WGX) (OTCQX: WGXRF) ("Westgold") have agreed to combine in a merger pursuant to which Westgold will acquire 100% of the issued and outstanding common shares of Karora ("Karora Shares") by way of a statutory plan of arrangement under the Canada Business Corporations Act ("CBCA") ("Transaction").
Karora shareholders will receive 2.5241 Westgold fully paid ordinary shares ("Westgold Shares"), A$0.68 (C$0.611) in cash and 0.30 of a share in a new company to be spun-out from Karora ("SpinCo") for each Karora Share held at the closing of the Transaction ("Offer Consideration").
Upon completion of the Transaction, existing Westgold and Karora shareholders will own approximately 50.1% and 49.9% of Enlarged Westgold, respectively.
The Transaction has been unanimously approved by the boards of directors of Westgold and Karora, and Karora's board of directors unanimously recommends that Karora shareholders vote in favour of the Transaction.

Sustainable Green Team (SGTM) Signs Memorandum of Understanding Agreement for Southeastern U.S. Waste Management Project

Retrieved on:

Friday, March 22, 2024

Partnership, Southeastern United States, MOU, Waste management, OTCQX, Green Team, Agreement, Renewable energy

ORLANDO, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Sustainable Green Team, Inc. (OTCQX: SGTM) ($SGTM) ("SGTM" or "the Company"), a leading provider of sustainable waste management solutions, announced signing a Memorandum of Understanding (MOU) agreement for a waste management project in the southeastern United States.

Key Points:

ORLANDO, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Sustainable Green Team, Inc. (OTCQX: SGTM) ($SGTM) ("SGTM" or "the Company"), a leading provider of sustainable waste management solutions, announced signing a Memorandum of Understanding (MOU) agreement for a waste management project in the southeastern United States.
"We are thrilled to enter into this Memorandum of Understanding for the 'Southeast USA Waste Management Project,'" Tony Raynor, CEO of the Sustainable Green Team , commented.
"This Agreement demonstrates our commitment to sustainable waste management and highlights the core technologies' effectiveness in addressing unique waste treatment processes throughout various industries.
The signing of this MOU marks another important milestone for SGTM and furthers its position as a leader in sustainable waste management solutions.

Metasphere Enters Into Definitive Agreement With Bluesphere Ventures Inc.

Retrieved on:

Thursday, March 21, 2024

Metaverse, Bitcoin, Ent, GST, Agreement, Partnership, Blockchain, Social media, FRA, News, OTC, Marketing, Cryptocurrency

Instead, ENTS will be developed on the Bitcoin Runes protocol, ensuring a robust and scalable foundation for the game's ecosystem.

Key Points:

Instead, ENTS will be developed on the Bitcoin Runes protocol, ensuring a robust and scalable foundation for the game's ecosystem.
The project collaboration between Metasphere and Bluesphere will focus on delivering key components for "Ents World".
Pursuant to the Agreement, Metasphere will develop a comprehensive presentation and website outlining Ents World's concept, features, and the impact on environmental restoration.
As of the date hereof, to Metasphere’s knowledge, Fairfax (including its directors and officers) does not own any securities of Metasphere and maintains an arm's-length relationship with the Company.

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on:

Thursday, March 21, 2024

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points:

ET to discuss the financial results and provide a business update
SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

OTTAWA BANCORP, INC. APPOINTS MARK ALCOTT TO BOARD OF DIRECTORS

Retrieved on:

Thursday, March 21, 2024

Exercise, Agreement, Shareholder, Bank, Sale, OSB, Community Bank, Share repurchase, Security (finance)

In the event Mr. Alcott is unable to serve as a director of the Company and Bank, the Company and Bank will appoint a replacement director chosen by the Stilwell Group.

Key Points:

In the event Mr. Alcott is unable to serve as a director of the Company and Bank, the Company and Bank will appoint a replacement director chosen by the Stilwell Group.
Mr. Alcott has agreed to similar restrictions under the Agreement, but may acquire shares of Company common stock.
“We have been looking to add experienced members to serve on our Boards, particularly following several retirements from the Board.
The Stilwell Group had previously submitted a notice of intent to nominate Mr. Alcott to the Company’s Board.

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on:

Thursday, March 21, 2024

Research, Toxicity, Bone disease, Agreement, Osteogenesis imperfecta, DAR, AML, Risk, Patient, MMAE, Mouse, OI, Public expenditure, Plaque, Apolipoprotein E, PRS, IND, ARIA, GMP, Osteoporosis, CRC, Workforce, Use, ADC, Osteoarthritis, FDA, GLP, Pharmaceutical industry

We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.

Key Points:

We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.
Selected our first antibody drug conjugate (ADC) candidate of a potential of three from our collaboration with LegoChem Biosciences, Inc. (LegoChem).
Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products.
Implemented a restructuring plan to reduce operating costs and better align our workforce with the needs of our business.

Significant Copper and Gold Mineralization Located on Georgetown Project, Australia

Retrieved on:

Wednesday, March 20, 2024

Kidston operated from 1985 to 2001 and was one of Australia’s largest historical gold producers producing 5.1 million ounces (145 tonnes) of gold*.

Key Points:

Kidston operated from 1985 to 2001 and was one of Australia’s largest historical gold producers producing 5.1 million ounces (145 tonnes) of gold*.
EMU’s sampling program was designed to assess a number of higher-priority prospects within the Georgetown Project tenements utilizing termite mound and outcrop rock chip geochemistry.
EMU’s announcement “ Exploration Update Georgetown, Scale Potential Confirmed ” dated March 4 2024, provides details of the work conducted and interpretation of sampling results.
The copper mineralization is now almost exclusively supergene altered to the copper oxide assemblage chrysocolla, malachite, tenorite, cuprite, and sooty chalcocite (Figures 5 and 6).

Feutune Light Acquisition Corporation Announces Stockholder Approval for Extending Business Combination Deadline and Merger Agreement Amendment with Thunder Power Holdings Limited

Retrieved on:

Wednesday, March 20, 2024

Accounting, TPH, Plan, Agreement, Business analyst, Trust, Special, Security (finance)

In addition, FLFV agreed with Thunder Power Holdings Limited (“TPH”) to amend Agreement and Plan of Merger (“Merger Agreement”) to confirm that TPH will continue to provide extension payments for the FLFV to extend its Combination Deadline.

Key Points:

In addition, FLFV agreed with Thunder Power Holdings Limited (“TPH”) to amend Agreement and Plan of Merger (“Merger Agreement”) to confirm that TPH will continue to provide extension payments for the FLFV to extend its Combination Deadline.
The Special Meeting is the second such meeting since July 2023 to extend the Combination Deadline.
Pursuant the current Merger Agreement, TPH agreed to provide loans to FLFV to be deposited into the Trust Account as monthly extension payments to extend the deadline for completing the Business Combination under the Current Charter until March 21, 2024.
In order to extend the Combination Deadline from March 21, 2024 to April 21, 2024, an aggregate of $60,000 Monthly Extension Payment was deposited into the Trust Account on March 19, 2024.

Titan Announces Merger Agreement with Conavi

Retrieved on:

Monday, March 18, 2024

TSX Venture Exchange, Agreement, Health Canada, IP, OCT, RAS, Chairperson, Toronto Stock Exchange, Consolidation, Combined, Reverse, Concurrency, Food, TMD, TSX, Transaction, IVUS, Security (finance)

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.

Key Points:

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.
Under the terms of the Agreement, Titan will acquire all of the issued and outstanding shares of Conavi (the “Conavi Shares”) and in exchange Conavi shareholders will be issued common shares of Titan (the “Combined Entity Shares”).
Throughout 2023, it was made clear to Titan that a merger with another RAS company was not a viable option and Titan broadened its search for a merger partner beyond RAS.
The Titan Board is unanimous in its decision to execute the Amalgamation Agreement and to recommend this Transaction to its shareholders (the “Titan Shareholders”).